Showing 3941-3950 of 7113 results for "".
- Vial Names Dr. Mark Lebwohl to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-names-dr-mark-lebwohl-to-scientific-advisory-board/2461091/The Vial Dermatology CRO has added Mark Lebwohl, MD, MPH to the Vial Scientific Advisory Board. Dr. Lebwohl will lend his expertise to the Vial CRO team and leading sponsors working to advance the Dermatology research field.<
- US Senate Passes Dr. Lorna Breen Acthttps://practicaldermatology.com/news/us-senate-passes-lorna-breen-act/2461090/The US Senate has passed the bipartisan Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667). The bill previously was passed by the US House of Representatives, and now goes to President Biden to be signed into law. Once signed, the Dr. Lorna Breen Health Care
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data als
- Business News: Taro to Acquire Alchemee From Galdermahttps://practicaldermatology.com/news/business-news-taro-to-acquire-alchemee-from-galderma/2461087/Taro Pharmaceutical Industries Ltd. Is buying Alchemee, formerly The Proactiv Company, from Galderma. The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed. "We are exc
- Phase 2b Study: AOBiome Therapeutics' Topical B244 Improves Itch, ADhttps://practicaldermatology.com/news/phase-2b-study-aobiome-therapeutics-topical-b244-improves-itch-ad/2461086/AOBiome Therapeutics’ B244 showed positive results from for both Pruritus and Atopic Dermatitis, according to a Phase 2b trial. AOBiome's B244 platform is a patented, proprietary, topical and intranasal formulation. Once deployed, B244 produces nitric
- LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United Stateshttps://practicaldermatology.com/news/leo-pharma-as-appoints-brian-hilberdink-new-president-of-leo-pharma-inc-united-states/2461084/LEO Pharma A/S appointed Brian Hilberdink as the new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022. Brian Hilberdink joins LEO Pharma from Novo Nordisk, Inc., in the U.S. where he served as Senior Vice President of Sales.<
- PCA SKIN Looks to Space for Next Breakthrough in Skin Healthhttps://practicaldermatology.com/news/pca-skin-looks-to-space-for-next-breakthrough-in-skin-health/2461077/PCA SKIN plans to send the first-ever private sector skin health experiment to the International Space Station (ISS). The experiment, sponsored by the ISS National Lab, will explore the effects of microgravity on skin-related biomarkers in an effort to guide future product innovat
- Study: Nutrafol's Core Products Provide Benefits Across Sexes, Ethnicitieshttps://practicaldermatology.com/news/study-nutrafols-core-products-provide-benefits-across-sexes-ethnicities/2461068/Nutrafol’s core products provide improvement in hair growth, coverage, density, and volume across diverse ethnicities, results of a new study show. The six-month, single blind study was conducted by Dr. Sophia Kogan, Tess Marshall, and Dr. Isabelle Raymond to test the effecti
- Study: Bile Acids May Improve Skin Inflammation in Psoriasishttps://practicaldermatology.com/news/study-bile-acids-may-improve-skin-inflammation-in-psoriasis/2461067/Taking bile acids may help control inflammation caused by psoriasis, a UC Davis Health study has found. The study, published in the Journal of Investigative Dermatolog
- Biofrontera Updates Patient Recruitment for Ameluz-PDT Trialhttps://practicaldermatology.com/news/biofrontera-updates-patient-recruitment-for-ameluz-pdt-trial/2461066/Fully 70 percent of the planned 186 patients have been enrolled in Biofrontera Inc.'s phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (Ameluz-PDT) in combination with the BF-RhodoLED lamp in the U.S, the company repor